

## CASE REPORTS

# Taming the Neurogenic Storm: Targeted Pharmacotherapy for Central Fever in Neurointensive Care: A Case Report

Kunal Kumar Sharma<sup>1</sup>, Rachna Bajaj<sup>2</sup>

## HOW TO CITE THIS ARTICLE:

Kunal Kumar Sharma, Rachna Bajaj. Taming the Neurogenic Storm: Targeted Pharmacotherapy for Central Fever in Neurointensive Care: A Case Report. Ind J Anesth Analg. 2026; 13(3): 145-150.

## ABSTRACT

Central fever is a non-infectious, neurogenic hyperthermia arising from thalamic injury. It complicates the clinical course of patients in neurointensive care units by closely mimicking infectious sepsis, often leading to diagnostic dilemmas and the inappropriate overuse of broad-spectrum antimicrobials. The underlying mechanism involves the disruption of hypothalamic thermoregulatory pathways and secondary neuroinflammation. Emerging advanced neuromonitoring techniques further assist in differentiating autonomic dysregulation from infection.

We present the clinical course of two neurocritically ill patients who developed refractory central fever. The report discusses successful resolution of fever in these patients. Maintaining a high clinical suspicion for central fever following the systematic exclusion of sepsis is paramount. Prompt intervention with targeted therapies like diclofenac rapidly controls temperature, safeguards the brain from secondary metabolic stress, and prevents antimicrobial abuse.

## KEYWORDS

• Fever • Diclofenac • Brain Injury • Bromocriptine

## INTRODUCTION

Central fever is a non-infectious, high-grade, persistent fever that is unresponsive to antibiotics and mimics sepsis.<sup>1</sup> Accurate identification is essential to avoid antibiotic overuse and to implement effective symptom control. Management relies on targeted non-steroidal anti-inflammatory drugs like

diclofenac, which blocks central prostaglandin synthesis. Refractory cases, or those presenting with paroxysmal sympathetic hyperactivity (PSH), may benefit from secondary agents such as bromocriptine, chlorpromazine, baclofen, propranolol, or clonidine to modulate specific central adrenergic, dopaminergic, or GABAergic pathways.<sup>2</sup> This report of two cases

## AUTHOR'S AFFILIATION:

<sup>1</sup> Assistant Professor, Neuroanesthesia Division, Indira Gandhi Medical College, Shimla, Himachal Pradesh, India.


<sup>2</sup> Resident, Department of Anesthesia, Indira Gandhi Medical College, Shimla, Himachal Pradesh, India.

## CORRESPONDING AUTHOR:

Kunal Kumar Sharma, Assistant Professor, Neuroanesthesia Division, Indira Gandhi Medical College, Shimla, Himachal Pradesh, India.

E-mail: kunaal\_kumar@yahoo.com

➤ Received: 04-06-2026 ➤ Accepted: 03-07-2026



Creative commons non-commercial CC BY-NC: This article is distributed under the terms of the creative commons attribution non-commercial 4.0 License (<http://www.creativecommons.org/licenses/by-nc/4.0/>) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the Red Flower Publication and Open Access pages (<https://rfppl.co.in>)

adheres to the CARE (Case Report) guidelines of EQUATOR network.

## CASE DESCRIPTION 1

A 66-year-old female with type 2 diabetes, a 15-year history of uncontrolled hypertension, and a 3-year history of hypothyroidism presented with a right thalamic infarct and aspiration pneumonitis. Severe hypoxia (SpO<sub>2</sub> 70%) necessitated endotracheal intubation and mechanical ventilation on SIMV-PC mode.

She subsequently developed extreme hyperthermia (up to 105°F) that failed to respond to broad-spectrum antibiotics, including piperacillin-tazobactam, meropenem, vancomycin, clindamycin, and levofloxacin. Serial imaging and cultures revealed no definitive infectious source. Neuroimaging demonstrated a right lentiform infarct, cerebellar atrophy, periventricular ischemic changes, and bilateral white matter demyelination. After thoroughly excluding infection, a diagnosis of central fever was

established. The initiation of a continuous intravenous diclofenac infusion achieved gradual and sustained resolution of her fever.


## CASE DESCRIPTION 2

A 60-year-old male presented with a severe traumatic brain injury following a motor vehicle accident. Neuroimaging revealed an acute subarachnoid hemorrhage (SAH) involving the right frontoparietal and occipital regions and the mesencephalic cistern. Associated polytrauma included multiple facial fractures, a rib fracture, a vertebral fracture (D12-L1), and left hemiplegia.


Within 36 hours of admission, his Glasgow Coma Scale (GCS) score deteriorated from E<sub>1</sub>V<sub>1</sub>M<sub>5</sub> to E<sub>1</sub>V<sub>1</sub>M<sub>4</sub>. He developed a persistent, high-grade fever unresponsive to empiric antibiotics and supportive care. Extensive clinical evaluations and cultures were entirely negative for an active infectious source. He was managed on the lines of central fever, resulting in an immediate positive response and subsequent complete resolution of his hyperthermia.

## Timeline of Clinical Course and Management

### CASE 1: 66-Year-Old Female with Right Thalamic Infarct and Central Fever



### CASE 2: 60-Year-Old Male with Severe Head Injury and Central Fever



Abbreviations: GCS – Glasgow Coma Scale; RTA – Road Traffic Accident; SAH – Subarachnoid Hemorrhage; ICU – Intensive Care Unit; SIMV-PC – Synchronized Intermittent Mandatory Ventilation–Pressure Control; PIP-TAZ – Piperacillin–Tazobactam; NSAIDs – Nonsteroidal Anti-inflammatory Drugs.

Figure 1: Timeline of clinical course of the two patients

## DISCUSSION

Central fever remains a diagnosis of exclusion in neurosurgical intensive care units, occurring most commonly after traumatic brain injury, SAH, intracerebral hemorrhage, hypothalamic injury, or major cranial surgery. The underlying pathophysiology involves the disruption of hypothalamic thermoregulatory pathways, neuroinflammation, localized cytokine release, autonomic dysfunction, and impaired central temperature control. Differentiating central fever from infectious causes is highly challenging because both conditions frequently coexist in critically ill neurosurgical patients.

Central fever affects 23–37% of patients with acute brain injury, particularly traumatic brain injury (TBI), SAH, and large ischemic strokes. It typically presents with a sudden onset, high-grade temperature ( $>39^{\circ}\text{C}$ ), and an absence of diurnal variation.<sup>3</sup>

While frequently confused with nosocomial infections, key diagnostic indicators supporting central fever include: (i) A normal or non-rising white blood cell (WBC) count, (ii) sterile cultures across all sites, (iii) non-responsiveness to broad-spectrum antibiotics, (iv) neuroimaging evidence of CNS injury, especially involving the hypothalamus, brainstem, or basal ganglia.

Structural lesions affecting critical neurovascular and hypothalamic-adjacent areas further exacerbate thermoregulatory failure. For instance, Rao et al. documented a tuberculum sella meningioma causing vascular compression and neurological deficits, demonstrating how pathology in the sellar and suprasellar regions disrupts neighboring neural architectures. Although fever was not a presenting feature in that specific case, lesions near hypothalamic pathways reinforce the neuroanatomical foundation of central thermoregulatory dysfunction.<sup>4</sup>

The paradigm for understanding recovery from severe neurological injury continues to evolve. Recent shifts in coma management emphasize advances in neurocritical care, multimodal neuromonitoring, and the mechanisms governing consciousness recovery. These developments are highly relevant because central fever often occurs in patients with impaired consciousness, where precise neurological tracking is vital to

differentiate fever-induced deterioration from the progression of primary brain injuries.<sup>5</sup>

Once infection is ruled out, targeted antipyretic therapy is paramount. Diclofenac demonstrates consistent efficacy in central fever due to its potent cyclooxygenase (COX) inhibition and central prostaglandin synthesis blockade. Continuous intravenous diclofenac infusion is well-documented in neurocritical care literature when alternative methods fail; conversely, acetaminophen monotherapy is often insufficient, and external cooling devices serve only an adjunctive role.

While prophylactic antipyretics remain under investigation, Giaccari et al. described a protocol utilizing an initial diclofenac sodium bolus (0.2 mg/kg over 30 minutes), followed by a continuous infusion of 75 mg in 50 ml of normal saline at 2–3 ml/hr to achieve effective fever suppression.<sup>6</sup>

For refractory cases, or those associated with specific clinical syndromes, alternative agents target distinct pathways. Bromocriptine is a dopamine agonist that acts on hypothalamic thermoregulation via D2 receptor stimulation. Central dopamine depletion is hypothesized to drive brain injury-induced hyperthermia, making bromocriptine highly effective in neuroleptic malignant syndrome (NMS) and central fevers tied to basal ganglia or hypothalamic injuries.<sup>7</sup> It serves as a valuable second-line option if NSAIDs fail, particularly in patients with thalamic or basal ganglia insults (as seen in Case 1) or during paroxysmal sympathetic hyperactivity (PSH).

Chlorpromazine is a phenothiazine antipsychotic that acts on central dopamine, serotonin, and histamine receptors. Its anticholinergic and sedative properties help dampen hyperactive hypothalamic pathways, serving as a second-line option for severe central fevers or NMS.<sup>8</sup> While beneficial for managing concurrent agitation, its potential to cause detrimental systemic hypotension limits its utility in neurocritically ill patients.

Baclofen is a GABA<sub>B</sub> receptor agonist and central muscle relaxant that reduces excitatory neurotransmission, blunting sympathetic overactivity.<sup>9</sup> It is particularly useful when central fever coexists with the spasticity and rigidity of PSH, or in spinal cord injuries, though risks of hypotonia and respiratory depression at high doses limit its intensive care application.



Propranolol is a beta-adrenergic blocker that mitigates peripheral sympathetic activation (e.g., tachycardia, hypertension), indirectly supporting temperature regulation. It serves as an excellent adjunct when central fever is accompanied by autonomic dysregulation in severe neurotrauma or SAH, and has demonstrated a mortality benefit by blunting catecholamine surges. The patient in Case 2 may have benefited from propranolol if systemic sympathetic overdrive had emerged.<sup>10</sup>

Clonidine is a central alpha-2 agonist that reduces sympathetic outflow, thereby dampening central thermoregulatory overdrive. It is highly effective in managing

PSH presentations involving fever, tachycardia, diaphoresis, and hypertension, preventing recurrent febrile spikes. Clonidine provides additional benefits to patients with marked autonomic instability by modulating sympathetic storms.<sup>11</sup>

While diclofenac successfully managed the patients in this series, adjuncts like bromocriptine, clonidine, and propranolol should be reserved for NSAID-refractory cases, PSH, or neurotrauma involving autonomic centers. Integrating these therapies can optimize autonomic control, reduce ICU length of stay, and minimize complications from sustained hyperthermia. We summarize these pharmacological options in the table below.

**Table 1:** Summary of potential role of drugs mitigating central fever

| Therapy        | Mechanism of Action                                                                            | Clinical Context / Indication                                                                                                                               | Relevance to Present Cases                                                                                                                            |
|----------------|------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------|
| Diclofenac     | Cyclooxygenase (COX) inhibition leading to suppression of prostaglandin-mediated thermogenesis | Considered a first-line pharmacological option for central fever after exclusion of infectious causes                                                       | Produced sustained defervescence in <b>Case 1 (thalamic infarct)</b> and supported the diagnosis of central fever                                     |
| Bromocriptine  | Dopaminergic agonist that modulates hypothalamic thermoregulatory pathways                     | Useful in refractory central fever, particularly in patients with basal ganglia or thalamic injury when fever persists despite NSAID therapy                | Could be considered as a second-line option if fever recurs or becomes refractory in <b>Case 1</b>                                                    |
| Chlorpromazine | Central dopamine antagonism with hypothalamic inhibition and sedative effects                  | May be beneficial in refractory central hyperthermia, autonomic agitation, or situations overlapping with neuroleptic malignant syndrome-like presentations | Potential rescue therapy for persistent fever unresponsive to conventional treatment                                                                  |
| Baclofen       | GABA-B receptor agonist reducing central excitatory output                                     | Particularly useful when fever occurs in association with paroxysmal sympathetic hyperactivity (PSH), spasticity, or autonomic dysregulation                | May have a role in severe neurotrauma patients exhibiting sympathetic storms                                                                          |
| Propranolol    | Non-selective $\beta$ -adrenergic blockade reducing sympathetic overactivity                   | Effective in fever associated with polytrauma, traumatic brain injury, subarachnoid hemorrhage, and PSH                                                     | Particularly relevant to <b>Case 2 (severe head injury with SAH and polytrauma)</b> where adrenergic hyperactivity may contribute to persistent fever |

Recent advances in neurophysiological monitoring have deepened our understanding of altered brain states in critically ill patients. Anesthetic states are inherently multidimensional and may decouple from conventional electroencephalographic (EEG) indices. For example, paradoxical bispectral index-burst suppression combinations signal neural inertia and complex transitions between states of consciousness. Such phenomena underscore the intricate relationship between cerebral network connectivity and autonomic function—mechanisms that likely participate in the dysregulated thermoregulation of central fever.<sup>12</sup>

The evolving emphasis on objective neurophysiological monitoring has also extended beyond EEG. Photoacoustic detection of propofol in exhaled breath is a novel approach for monitoring anesthetic depth in neuroanesthesia.<sup>13</sup> Continuous multimodal monitoring strategies such as these may contribute to more precise assessment of neurological status and facilitate differentiation between altered consciousness due to infection, metabolic disturbances, drug effects, or primary neurological injury in febrile neurosurgical patients.

Maintaining adequate cerebral perfusion is fundamental, as hyperthermia accelerates cerebral metabolic demand and exacerbates secondary brain injury. Given the physiological nonequivalence of temporary flow-reduction techniques in neurovascular surgery, preserving stable cerebral blood flow and minimizing ischemic insults remains crucial. Because hypothalamic and diencephalic injuries drive central fever, optimizing cerebral perfusion may theoretically shield these sensitive thermoregulatory centers from secondary degradation.<sup>14</sup>

Furthermore, Fourier-based EEG analysis holds promise for predicting anesthetic emergence during non-neurosurgical procedures in neurosurgical cohorts. Advanced signal processing may eventually help characterize the specific cerebral dysfunction that underlies central autonomic disturbances and impaired thermoregulatory control.<sup>15</sup>

Collectively, these contemporary insights emphasize the expanding roles of advanced neuromonitoring, cerebral perfusion management, and brain-state dynamics in neurocritical care. Although direct links to central fever require further investigation, these frameworks illuminate the physiological disruptions underlying thermoregulatory failure and will guide future diagnostic and therapeutic approaches in the neuro-ICU.

Ultimately, managing central fever remains largely empirical, focused on modulating dysregulated central pathways. Diclofenac remains an effective, high-utility first-line agent, as demonstrated by prompt defervescence in our patient with a thalamic infarct. Refractory cases or those with profound sympathetic activation warrant targeted choices: bromocriptine for hypothalamic/basal ganglia injuries, chlorpromazine for central hypothalamic inhibition, baclofen for PSH-associated rigidity, and adrenergic modulators (propranolol/clonidine) for severe neurotrauma or SAH. Our patients' positive responses following the rigorous exclusion of sepsis reinforce the validity of these targeted strategies.

## CONCLUSION

These two cases highlight the importance of early recognition of central fever in acute brain injury. Once sepsis is ruled

out, targeted therapy with a continuous diclofenac infusion can rapidly resolve hyperthermia, improve patient comfort, and prevent antibiotic overuse. Clinicians must maintain a high index of suspicion for central fever in the neurointensive care whenever high-grade pyrexia persists despite broad-spectrum antimicrobial coverage and sterile cultures.

**Conflict of interest:** None

## REFERENCES

1. Jang SH, Seo YS. Neurogenic fever due to injury of the hypothalamus in a stroke patient: Case report. *Medicine* 2021;100:13 (e24053).
2. Goyal K, Garg N, Bithal P. Central fever: a challenging clinical entity in neurocritical care. *J Neurocrit Care* 2020;13(1):19-31.
3. Hocker SE, Tian L, Li G, Steckelberg JM, Mandrekar JN, Rabinstein AA. Indicators of central fever in the neurologic intensive care unit. *JAMA Neurol.* 2013;70(12):1499-1504.
4. Rao K, Sharma KK, Thakur DS. Tuberculum Sella Meningioma Compressing Anterior Cerebral Artery Causing Optic Nerve Symptoms-A Case Report. *Turk Neurosurg.* 2025;35(6):983-986. doi: 10.5137/1019-5149.JTN.48026-24.2. PMID: 41165378.
5. Sharma KK, Bharti. Curing Coma: The Emerging Paradigm Shift. *J Trauma Anaesth Resusc Crit Care.* 2025;1:56-60. doi: 10.25259/JTARCC\_14\_2025
6. Giaccari LG, Pace MC, Passavanti MB, Sansone P, Esposito V, Aurilio C, Pota V. Continuous intravenous low-dose diclofenac sodium to control a central fever after ischemic stroke in the intensive care unit: a case report and review of the literature. *J Med Case Rep.* 2019;13(1):373.
7. Amin SJ, Aghajan Y, Webb AJ. Clinical experience with bromocriptine for central hyperthermia after brain insult. *Brain Inj* 2024;38(8):652-658.
8. Iban Ö, Zora ME, Akçay BD, Çelik JB, Çiçekci F, Baş MA, Duman A. The acute effect of chlorpromazine on body temperature in intensive care unit patients. *Genel Tıp Dergisi.* 2022; 32(6):658-665.
9. Jiyong Iruon Park, Sung-Kyun Hwang. Central Hyperthermia Due to Intracerebral Hemorrhage Treated with Ba clofen: A Case Report. *The Nerve* 2021;7(2):103-105.

10. Reinert JP, Kormanyos Z. Pharmacologic Management of Central Fever: A Review of Evidence for Bromocriptine, Propranolol, and Baclofen. *J Pharm Technol.* 2023;39(1):29-34.
11. Kelesidis T, Kelesidis I. Unexplained high fever in an elderly patient treated with clonidine, duloxetine, and atorvastatin. *Clin Ther.* 2009;31(12):2894-289.
12. Sharma KK. Paradoxical Bispectral Index-Burst Suppression Combinations as Evidence of Neural Inertia and Multidimensional Anesthetic States. *Anesth Analg.* 2026 May 25. doi: 10.1213/ANE.0000000000008100.
13. Sharma KK. Photoacoustic detection of propofol in breath gas for monitoring depth of anaesthesia: application in neuroanaesthesia. Comment on *Br J Anaesth* 2025; 135: 1203-11. *Br J Anaesth.* 2026 May;136(5):1665-1666.
14. Sharma KK. Physiological Nonequivalence of Temporary Flow-Reduction Techniques in Neurovascular Surgery: A Necessary Clarification. *J Neurosurg Anesthesiol.* 2026 Jan 21.
15. Sharma KK, Sharma S, Takkar V. Fourier-based electroencephalography analysis for predicting anaesthetic emergence: Proof-of-concept in a neurosurgical patient undergoing non-neurosurgical procedures. *Indian J Anaesth.* 2026 Apr;70(4):578-583.